Leonardo is the exclusive provider of a proprietary multistage drug delivery platform initially targeting the treatment of cancer. The first stage consists of silicon nanoparticles that are rationally designed to circumvent the biological barriers between injection and the target site. The non-toxic silicon nanoparticles can carry a variety of second stage delivery vehicles.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
Makefield Therapeutics has licensed Intellectual Property covering a novel platform technology from Albert Einstein College of Medicine of Yeshiva University for the generation of powders comprised of hydrogel/glassy matrix (hybrid) nanoparticles that in a first application are delivering controlled and sustained therapeutic levels of gaseous nitric oxide
MSI's technology for multi-step multi-analyte chemiluminescent assays combines microfluidics, nanotechnology, and optoelectronics designed for both Immunoassay and Nucleic Acid Hybridization based applications.
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering™ platform enables the design, engineering and manufacturing of Hybrid water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
MicroConstants is a GLP-compliant Contract Research Organization (CRO) dedicated to providing premier quality bioanalytical, drug metabolism, pharmacokinetic, formulation and immunoassay support services to pharmaceutical and biotech companies worldwide.
Micronit Microfluidics focuses on developing, prototyping and manufacturing lab-on-a-chip products. Micronit has extensive experience supplying microfluidic solutions to the life sciences industry. Capabilities include nanofluidic channels (depth down to 100 nm).